Focused On-demand Library for Ephrin-A5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P52803

UPID:

EFNA5_HUMAN

Alternative names:

AL-1; EPH-related receptor tyrosine kinase ligand 7

Alternative UPACC:

P52803

Background:

Ephrin-A5, known alternatively as AL-1 and EPH-related receptor tyrosine kinase ligand 7, plays a pivotal role in neuronal, vascular, and epithelial development. It functions as a cell surface GPI-bound ligand for Eph receptors, facilitating crucial processes such as migration, repulsion, and adhesion through bidirectional signaling. Ephrin-A5's interaction with Eph receptors, including EPHA3 and EPHA2, influences cell-cell adhesion, cytoskeletal organization, lens transparency, axon fasciculation, and glucose-stimulated insulin secretion.

Therapeutic significance:

Understanding the role of Ephrin-A5 could open doors to potential therapeutic strategies, particularly in enhancing neuronal, vascular, and epithelial development, as well as in managing diabetes through the regulation of insulin secretion.